End of treatment RNA-positive/sustained viral response in an individual with acute hepatitis C virus infection treated with direct-acting antivirals.
作者信息
Shteyer Eyal, Dahari Harel, Gafanovich Ina, Dery Ilana, Wolf Dana, Cotler Scott J, Lurie Yoav
机构信息
Pediatric Liver Unit, Shaare Zedek Medical Center, 12 Beit, Jerusalem, 91031, Israel.
The Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Loyola University Medical Center, Maywood, IL, USA.
出版信息
Therap Adv Gastroenterol. 2017 May;10(5):429-430. doi: 10.1177/1756283X17694808. Epub 2017 Feb 1.
Abstract
摘要
相似文献
1
End of treatment RNA-positive/sustained viral response in an individual with acute hepatitis C virus infection treated with direct-acting antivirals.接受直接抗病毒药物治疗的急性丙型肝炎病毒感染个体的治疗结束时RNA阳性/持续病毒学应答
Therap Adv Gastroenterol. 2017 May;10(5):429-430. doi: 10.1177/1756283X17694808. Epub 2017 Feb 1.
2
Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.丙型肝炎病毒相关性肾小球疾病的免疫抑制和抗病毒治疗：长期随访
Int J Artif Organs. 2018 Jun;41(6):306-318. doi: 10.1177/0391398818762358. Epub 2018 Mar 29.
3
Use of direct-acting antivirals for hepatitis C viral infection and association with intrahepatic cholangiocarcinoma: Is there a linkage?直接作用抗病毒药物用于丙型肝炎病毒感染及其与肝内胆管癌的关联：是否存在联系？
J Oncol Pharm Pract. 2019 Oct;25(7):1743-1748. doi: 10.1177/1078155218800147. Epub 2018 Sep 26.
4
HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies.直接作用抗病毒药物时代 HCV 核心抗原替代 HCV RNA 检测：回顾性筛查和诊断队列研究。
Lancet Gastroenterol Hepatol. 2018 Dec;3(12):856-864. doi: 10.1016/S2468-1253(18)30271-1. Epub 2018 Sep 28.
5
Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.美国丙型肝炎病毒感染全口服直接抗病毒药物的初始吸收率、治疗时间和真实世界疗效：一项回顾性队列分析。
PLoS One. 2019 Aug 22;14(8):e0218759. doi: 10.1371/journal.pone.0218759. eCollection 2019.
6
SUSTAINED VIROLOGIC RESPONSE RATE IN CHRONIC HEPATITIS C PATIENTS THROUGH DIRECT-ACTING ANTIVIRALS THERAPY.通过直接抗病毒药物治疗慢性丙型肝炎患者的持续病毒学应答率
Arq Gastroenterol. 2019 Oct-Dec;56(4):394-398. doi: 10.1590/S0004-2803.201900000-79.
7
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.直接作用抗病毒疗法可降低丙型肝炎肝硬化患者肝癌复发率。
Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.
8
Neutrocyte-to-lymphocyte ratio predicts the presence of a replicative hepatitis C virus strand after therapy with direct-acting antivirals.中性粒细胞与淋巴细胞比值可预测直接作用抗病毒药物治疗后复制性丙型肝炎病毒链的存在。
Clin Exp Med. 2019 Aug;19(3):401-406. doi: 10.1007/s10238-019-00561-y. Epub 2019 May 24.
9
Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients.直接作用抗病毒药物治疗后新发肝细胞癌的早期发生：与慢性丙型肝炎患者聚乙二醇干扰素治疗的比较
J Viral Hepat. 2018 Oct;25(10):1189-1196. doi: 10.1111/jvh.12918. Epub 2018 May 17.
10
Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report.一名丙型肝炎病毒感染患者在接受索磷布韦和维帕他韦治疗期间乙肝核心抗体呈阳性，其体内由乙肝病毒表面抗原免疫逃逸突变株维持的乙肝病毒再激活：病例报告
J Med Case Rep. 2019 Sep 22;13(1):299. doi: 10.1186/s13256-019-2232-3.
引用本文的文献
1
A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics.一种用于RNA介导病毒动力学的稳健高效数值方法。
Front Appl Math Stat. 2017 Oct;3. doi: 10.3389/fams.2017.00020. Epub 2017 Oct 31.
2
Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography.建模表明，在计算机断层扫描期间，受污染的微升血液体积导致了丙型肝炎的爆发。
PLoS One. 2019 Jan 15;14(1):e0210173. doi: 10.1371/journal.pone.0210173. eCollection 2019.
3
Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.在 DAA 作用下的 HCV 早期病毒动力学可能会优化代偿性肝硬化患者的治疗持续时间。
Liver Int. 2019 May;39(5):826-834. doi: 10.1111/liv.14014. Epub 2018 Dec 28.
4
Modeling how reversal of immune exhaustion elicits cure of chronic hepatitis C after the end of treatment with direct-acting antiviral agents.模拟直接作用抗病毒药物治疗结束后免疫衰竭逆转如何引发慢性丙型肝炎的治愈。
Immunol Cell Biol. 2018 Oct;96(9):969-980. doi: 10.1111/imcb.12161. Epub 2018 Jun 5.
本文引用的文献
1
Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies.接受索磷布韦联合疗法治疗的丙型肝炎病毒（HCV）患者治疗结束时RNA阳性/持续病毒学应答的发生率
Therap Adv Gastroenterol. 2017 Jan;10(1):68-73. doi: 10.1177/1756283X16672392. Epub 2016 Oct 17.
2
Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.不同索磷布韦为基础的抗病毒方案治疗过程中 HCV RNA 水平的临床价值。
J Hepatol. 2016 Sep;65(3):473-82. doi: 10.1016/j.jhep.2016.04.006. Epub 2016 Apr 13.
Zotero 插件